Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Med Chem ; 64(3): 1570-1583, 2021 02 11.
Article in English | MEDLINE | ID: mdl-33523674

ABSTRACT

Androgen receptor (AR) contributes to the progression of glioblastoma (GBM), and antiandrogen agents have the potential to be used for the treatment of GBM. However, AR mutation commonly happens in GBM, which makes the antiandrogen agents less effective. Heat shock 27 kDa protein (HSP27) is a well-documented chaperone protein to stabilize ARs. Inhibition of HSP27 results in AR degradation regardless of the mutation status of ARs, which makes HSP27 a good target to abolish ARs in GBM. Compound I is a HSP27 inhibitor that significantly induces AR degradation in GBM cells via the proteasomal pathway, and it selectively inhibits AR-overexpressed GBM cell growth with IC50 values around 5 nM. The compound also significantly inhibits in vivo GBM xenograft at 20 mg/kg and does not cause toxicity to mice up to 80 mg/kg. These results suggest that targeting HSP27 to induce AR degradation in GBM is a promising and novel treatment.


Subject(s)
Androgen Antagonists/pharmacology , Brain Neoplasms/metabolism , Glioblastoma/metabolism , HSP27 Heat-Shock Proteins/antagonists & inhibitors , Receptors, Androgen/drug effects , Androgen Antagonists/toxicity , Animals , Brain Neoplasms/genetics , Cell Line, Tumor , Drug Delivery Systems , Drug Design , Gene Expression Regulation, Neoplastic/drug effects , Glioblastoma/genetics , Humans , Mice , Models, Molecular , Molecular Docking Simulation , Mutation , Proteasome Endopeptidase Complex/drug effects , Receptors, Androgen/genetics , Small Molecule Libraries , Structure-Activity Relationship , Xenograft Model Antitumor Assays
2.
Bioorg Med Chem ; 27(8): 1517-1528, 2019 04 15.
Article in English | MEDLINE | ID: mdl-30833159

ABSTRACT

Previously synthesized tubulin inhibitors showed promising in vitro selectivity and activity against Human African Trypanosomiasis. Current aim is to improve the ligand efficiency and reduce overall hydrophobicity of the compounds, by lead optimization. Via combinatorial chemistry, 60 new analogs were synthesized. For biological assay Trypanosoma brucei brucei Lister 427 cell line were used as the parasite model and for the host model human embryonic kidney cell line HEK-293 and mouse macrophage cell line RAW 264.7 were used to test efficacy. Of the newly synthesized compounds 5, 39, 40, and 57 exhibited IC50s below 5 µM inhibiting the growth of trypanosome cells and not harming the mammalian cells at equipotent concentration. Comparably, the newly synthesized compounds have a reduced amount of aromatic moieties resulting in a decrease in molecular weight. Due to importance of tubulin polymerization during protozoan life cycle its activity was assessed by western blot analyses. Our results indicated that compound 5 had a profound effect on tubulin function. A detailed structure activity relationship (SAR) was summarized that will be used to guide future lead optimization.


Subject(s)
Trypanocidal Agents/chemistry , Trypanocidal Agents/pharmacology , Trypanosoma brucei brucei/drug effects , Tubulin Modulators/chemistry , Tubulin Modulators/pharmacology , Animals , Drug Design , Drug Discovery , HEK293 Cells , Humans , Mice , RAW 264.7 Cells , Trypanosomiasis, African/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL